Working… Menu

Open Label Extension Study for the Long-term Efficacy and Safety of FG-4592 in Dialysis and Non-dialysis Chronic Kidney Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01630889
Recruitment Status : Completed
First Posted : June 28, 2012
Last Update Posted : June 29, 2020
Information provided by (Responsible Party):

Brief Summary:
The purpose of this open-label extension study is to evaluate long-term efficacy and safety of FG-4592 in maintaining hemoglobin in dialysis and non-dialysis CKD patients who have completed the Treatment Period of an FG-4592 FibroGen-sponsored anemia study.

Condition or disease Intervention/treatment Phase
Chronic Kidney Disease End Stage Renal Disease Anemia Drug: FG-4592 Phase 2 Phase 3

Detailed Description:
This is an open-label, long-term maintenance study of FG-4592 anemia therapy in dialysis and non-dialysis Chronic Kidney Disease patients who have completed the Treatment Period of an FG-4592 FibroGen-sponsored anemia Study. Subjects assigned to FG-4592 in the previous study will continue to receive the same FG-4592 dose and dosing frequency, unless a dose adjustment is required. An optional treatment group may allow subjects assigned to placebo in the previous study to start active FG-4592 study treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Extension Study to Evaluate the Efficacy and Safety of FG-4592 for the Long-Term Maintenance Treatment of Anemia in Dialysis and Non-Dialysis Patients With Chronic Kidney Disease
Actual Study Start Date : May 2012
Actual Primary Completion Date : December 2019
Actual Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: FG-4592
FG-4592 Investigational Drug
Drug: FG-4592
Subjects previously randomized to FG-4592 will receive study medication on the same dosing frequency assigned at the last dose of the previous FibroGen study.
Other Name: Roxadustat

Primary Outcome Measures :
  1. Efficacy and Safety of FG-4592 treating anemia in dialysis and non-dialysis chronic kidney disease patients [ Time Frame: Up to 5 years. ]
    • Evaluation of the long-term efficacy and safety of FG-4592 in the maintenance of hemoglobin (Hb) in dialysis and non-dialysis patients in CKD.
    • Weekly FG-34592 doses and frequency of dose adjustments
    • Need for recue therapies, consisting of either blood transfusion, IV iron or erythropoietins
    • Safety: Vital signs, laboratory values, AEs and SAEs

Secondary Outcome Measures :
  1. Evaluate FG-4592 doses and dose adjustments. [ Time Frame: Up to 5 years. ]

    FG-4592 weekly total doses over time.

    Dose adjustment frequencies during study duration.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Minimum age 18 years
  2. Completed the Treatment Period of an ongoing FG-4592 FibroGen-sponsored anemia study in the U.S.

Exclusion Criteria

  1. Subjects assigned to epoetin alfa in a previous ongoing FG-4592 anemia study
  2. Pregnant or breastfeeding females
  3. Females of childbearing potential, unless using contraception as detailed in the protocol; male subjects with sexual partners of childbearing potential who are not on birth control unless the male subject agrees to use contraception
  4. Subjects who received FG-4592 in a previous study that did not demonstrate adequate hemoglobin response per the investigator's clinical judgment
  5. Any medical condition that in the opinion of the investigator may pose a safety risk to a subject in this study, or which may interfere with study participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01630889

Layout table for location information
United States, California
APEX Research
Riverside, California, United States, 92505
United States, Maryland
Greenbelt, Maryland, United States, 20770
United States, North Carolina
Mountain Kidney & HTN Associates, PA
Asheville, North Carolina, United States, 28801
United States, Texas
Arlington Nephrology
Arlington, Texas, United States, 76015
Puerto Rico
Consolidated Medical Plaza
Caguas, Puerto Rico, 00725
CAIMED School of Medicine
Ponce, Puerto Rico, 00716
San Juan, Puerto Rico, 00918
Sponsors and Collaborators
Layout table for investigator information
Study Director: Lona Poole, MD FibroGen
Layout table for additonal information
Responsible Party: FibroGen Identifier: NCT01630889    
Other Study ID Numbers: FGCL-4592-059
First Posted: June 28, 2012    Key Record Dates
Last Update Posted: June 29, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Keywords provided by FibroGen:
End Stage Renal Disease
Oral anemia treatment
Hemoglobin levels
Chronic Kidney Disease
Blood count
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Hematologic Diseases
Urologic Diseases
Renal Insufficiency